Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naïve HIV-2-infected patients: The ACHIEV2E collaboration study group

Clinical Infectious Diseases

Volumn 52, Issue 10, 2011, Pages 1257-1266

  Benard, Antoine ^a   Van Sighem, Ard ^e   Taieb, Audrey ^a   Valadas, Emilia ^f   Ruelle, Jean ^g   Soriano, Vicente ^h   Calmy, Alexandra ⁱ   Balotta, Claudia ^j   Damond, Florence ^c,d   Brun Vezinet, Franoise ^c,d   Chene, Genevive ^a,b   Matheron, Sophie ^c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e STICHTING HIV MONITORING   (Netherlands)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; DIDANOSINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; EUROPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79955376496     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir123     Document Type: Article

References (33)

1. Drylewicz J, Matheron S, Lazaro E, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-68. (Pubitemid 351317287)
2. Jaffar S, Wilkins A, Ngom PT, et al. Rate of decline of percentage CD41 cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:327-32.
3. Alabi AS, Jaffar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 2003; 17:1513-20. (Pubitemid 36900552)
4. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325-30. (Pubitemid 46744441)
5. Matheron S, Damond F, Benard A, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459-62.
6. Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20:347-8. (Pubitemid 38429408)
7. Tuaillon E, Gueudin M, Lemee V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004; 37:1543-9. (Pubitemid 39658189)
8. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD41 cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17(Suppl 3):S49-54. (Pubitemid 36951669)
9. Mullins C, Eisen G, Popper S, et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38:1771-9. (Pubitemid 38781672)
10. van der Ende ME, Prins JM, Brinkman K, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17(Suppl 3):S55-61. (Pubitemid 36951670)
11. World Health Organisation. World Health Organisation Antiretroviral therapy in adults and adolescents-recommendations for a public health approach-2010 revision. Available at: http:// www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 6 January 2011.
12. Benard A, Damond F, Campa P, et al. Good response to lopinavir/ ritonavir-containing antiretroviral regimens in antiretroviral-na?̈ve HIV-2-infected patients. AIDS 2009; 23:1171-3.
13. Drylewicz J, Eholie S, Maiga M, et al. First-year lymphocyte T CD41 response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS 2010; 24:1043-50.
14. Ruelle J, Roman F, Vandenbroucke AT, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8:21.
15. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-8. (Pubitemid 351522031)
16. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther 2004; 9:631-3. (Pubitemid 39150221)
17. Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088-91. (Pubitemid 351831850)
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2009; 1-161. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 6 January 2011.
19. Yeni P. Prise en charge medicale des personnes infectees par le VIH: rapport 2008. Available at: http://www.ladocumentationfrancaise.fr/ rapports-publics/084000593/. Accessed 6 January 2011.
20. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatmentrelated determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDS 2009; 23:903-14.
21. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90. (Pubitemid 44200639)
22. Ariyoshi K, Jaffar S, Alabi AS, et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. AIDS 2000; 14:339-44. (Pubitemid 30182429)
23. Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593-601. (Pubitemid 38402337)
24. Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008; 22:2073-4.
25. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, HeneineW. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65. (Pubitemid 38313948)
26. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2:e10.
27. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009; 199:1323-6.
28. Damond F, Matheron S, Peytavin G, et al. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. Antivir Ther 2004; 9:635-6. (Pubitemid 39150222)
29. Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197-201. (Pubitemid 39150384)
30. Rodes B, Holguin A, Soriano V, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38:1370-4. (Pubitemid 30216656)
31. Ntemgwa ML, Toni T, Brenner BG, et al. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother 2009; 53:708-15.
32. Gottlieb GS, Badiane NM, Hawes SE, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 2009; 48:476-83.
33. Gottlieb GS, Eholie SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069-72.